In the July 2009 issue of the Journal of Biomedical Science, there was a study published by Ahmed et al. entitled
Metabolic profiling of Parkinson's disease: evidence of biomarker
from gene expression analysis and rapid neural network detection.In this study, 1H nuclear magnetic resonance spectroscopy analysis was
carried out on plasma samples of 37 healthy controls and 43 drug-naive
patients with Parkinson's Disease. The patented "
Targeted Profiling" technology of
Chenomx NMR Suite was then used for the determination and quantification of 22 metabolites in the plasma. Partial least squares discriminant analysis (PLS-DA) showed that
pyruvate is the key metabolite, which contributes to the separation of
PD from control samples. Furthermore, gene expression analysis shows
significant (p < 0.05) change in expression of PDHB and NPFF genes leading to increased pyruvate concentration in blood plasma. Moreover, the implementation of 1H- NMR spectral pattern in neural network algorithm shows 97.14% accuracy in the detection of disease progression. They concluded the biomarker trajectories could go a long way to
facilitate the development of useful therapies. Moreover,
implementation of neural network will be a breakthrough in clinical
screening and rapid detection of PD.
To see the abstract and sign-in to read this paper
click here.
If you have published any material using Chenomx NMR Suite, please do not hesitate to
let us know so that we can mention it in this newsletter. We would love to see it!
For other publications, case studies, news, and application notes using Chenomx NMR Suite
click here.
